Jefferies cuts target for RxSight stock to USD 5.75
Jefferies has reduced its target for RxSight (RXST) stock to USD 5.75 from USD 6.50, maintaining a Hold rating. This adjustment follows RxSight's Q2 2026 revenue of USD 33.74 million, which exceeded consensus, alongside continued losses. The investment case now heavily centers on the execution of RxSight's commercial reset and the potential impact of its collaboration with Alcon.
Is the New Setup at RxSight (NASDAQ:RXST) Sustainable?
RxSight (NASDAQ:RXST) is currently under scrutiny due to tight financial conditions emphasizing the importance of funding runway and company-specific demand. The article questions whether the company's focus on adjustable intraocular lenses can lead to sustainable and repeatable execution. Investors are advised to look for strong internal disclosures from management regarding demand, delivery, and capital allocation rather than relying solely on market sentiment.
RxSight stock faces a lower Jefferies target at USD 5.75
RxSight, Inc. (RXST) reported a Q2 2026 adjusted loss of USD 0.29 per share, outperforming the consensus of USD 0.33, with revenues of USD 33.74 million. Despite the revenue beat and better-than-expected loss, the company remains unprofitable. Jefferies and Bank of America have both lowered their price targets for RxSight stock to USD 5.75 and USD 5.50 respectively, maintaining "Hold" and "Underperform" ratings, reflecting caution despite the quarterly performance.
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)
This article summarizes recent analyst ratings for two healthcare companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP). Bank of America Securities reiterated a Sell rating on RxSight with a $5.50 price target, while H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals with a $15.00 price target. The article also provides details on the analysts' rankings and the overall consensus ratings for both stocks.
RxSight stock falls 1.62 percent as target cuts mount
RxSight stock dropped 1.62 percent to USD 4.85 following analyst target cuts from Bank of America and Jefferies, despite Q2 2026 revenue exceeding consensus estimates. The company's management presented a turnaround plan focusing on Light Adjustable Lens growth amidst flat commercial performance and withdrawn 2026 guidance, making execution a critical factor for investor confidence. The stock is currently trading near its 52-week low.
RxSight Price Target Cut to $5.75/Share From $6.50 by Jefferies
Jefferies has lowered its price target for RxSight (NASDAQ: RXST) shares to $5.75 from $6.50. The firm maintained a "Buy" rating on the stock despite the revised price target.
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
Bank of America (BofA) indicates that RxSight (RXST) possesses upside potential contingent on its ability to expand its salesforce and implement utilization-growth initiatives. However, the company faces significant structural and competitive challenges that could impede this growth. Full details of BofA's analysis are available to premium subscribers.
RXSIGHT, INC. : JEFFERIES CUTS TARGET PRICE TO $5.75 FROM $6.50
Jefferies has reduced its target price for RXSIGHT, INC. (RXST.O) to $5.75 from $6.50. This information was reported by Reuters on September 22, 2026. The article's content reflects only the author's opinion and is not intended as investment advice.
BofA Adjusts Price Target on RxSight to $5.50 From $6.50
BofA has adjusted its price target for RxSight (RXST) to $5.50 from $6.50. Despite this change, the company currently holds an average analyst rating of "hold" with a mean price target of $7.57. The full MT Newswires article requires a premium subscription to view.
RxSight, Inc. (RXST) insider now holds 235,516 shares after option exercise
RxSight, Inc.'s Chief Business Development Officer, Eric Weinberg, exercised 35,168 stock options on September 15, 2026, increasing his direct holdings to 235,516 shares. He also holds significant indirect ownership through a trust and his spouse. The exercised options were fully vested.
RxSight (RXST) ends employee option swap after 91.9% take-up
RxSight (RXST) has completed its employee option exchange offer, with 91.9% of eligible options tendered and cancelled. This involved 205 employees exchanging 3.76 million option shares for new equity awards. The company subsequently granted new options to executives and restricted stock units to non-executive employees under its 2021 Equity Incentive Plan.
RxSight at wells fargo healthcare conference: reset centers on LAL growth
RxSight presented at the Wells Fargo 21st Annual Healthcare Conference, outlining a turnaround plan focused on increasing Light Adjustable Lens (LAL) utilization among existing surgeons rather than acquiring new accounts. The company plans to double its U.S. sales force through resource reallocation and emphasizes the strategic importance of its partnership with Alcon, which provides $200 million upfront and a 30% royalty on future sales. RxSight believes its LAL technology offers superior clinical outcomes and aims to position "adjustable cataract surgery" as a distinct category to drive future growth.
RxSight Officer Mark Wilterding to Sell 7,765 Shares Worth $54,044.40 to Cover Tax Withholding
RxSight officer Mark Wilterding is selling 7,765 shares of common stock, valued at approximately $54,044.40, to cover withholding taxes associated with the vesting of restricted stock unit awards. The transaction, authorized by attorney-in-fact Jim Schindler, occurred on September 2, 2026. This sale provides transparency regarding the purpose of the stock disposition for investors.
RxSight chief business development officer Eric Weinberg sells $14,205 in stock
RxSight's Chief Business Development Officer, Eric Weinberg, sold 2,041 shares of company stock worth $14,205 to cover tax obligations related to restricted stock unit vesting. This transaction is not a discretionary sale. Despite a 32.5% year-to-date decline, InvestingPro suggests the stock is undervalued, while recent positive Q2 2026 earnings were tempered by the withdrawal of full-year guidance and a reduced price target from Stifel due to competitive pressures.
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com
RxSight CFO Mark Wilterding sold 7,765 shares of the company's common stock for $54,044 to cover tax withholding obligations related to restricted stock unit vesting. This transaction followed the acquisition of 20,441 shares through RSU vesting. Despite the sale, Wilterding still holds a significant number of shares and RSUs, while the company recently reported better-than-expected Q2 2026 results but withdrew its full-year guidance due to ongoing business challenges.
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RxSight, Inc. announced its management is scheduled to participate in the Wells Fargo Healthcare Conference. The event will take place on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A webcast of the presentation will be available on the company’s investor relations website.
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RxSight, Inc. announced its management is scheduled to participate in the Wells Fargo Healthcare Conference on September 9, 2026, at 9:30 a.m. ET in Boston. A live and archived webcast of the presentation will be available on the company's investor relations website. RxSight is an ophthalmic medical device company known for its Light Adjustable Lens system, which allows post-cataract surgery vision customization.
RxSight (NASDAQ: RXST) refreshes documents for option exchange
RxSight, Inc. (NASDAQ: RXST) has amended its employee stock option exchange program, primarily to update the list of associated documents and materials. The Exchange Offer allows eligible employees to swap existing stock options for new equity awards under the terms of the Offer to Exchange dated August 10, 2026, and is tied to the company’s 2021 Equity Incentive Plan. This amendment does not alter the fundamental structure of the Exchange Offer itself.
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RxSight, Inc. announced its management will participate in the Wells Fargo Healthcare Conference on September 9, 2026, in Boston. A webcast of the presentation will be available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, offering the RxSight Light Adjustable Lens system for customized vision after cataract surgery.
Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST
Tocqueville Asset Management L.P. has made a new investment in RxSight, Inc. (NASDAQ:RXST), acquiring 265,000 shares valued at approximately $1.28 million, representing 0.64% of the company. Despite beating Q2 earnings estimates, RxSight remains unprofitable with a negative net margin. Institutional investors collectively own 78.78% of the company, and analysts have a consensus "Reduce" rating with an average price target of $8.37.
Steven Cohen’s Point72 discloses RxSight (RXST) stake
Steven Cohen's Point72 Asset Management, along with Point72 Capital Advisors, Inc., has disclosed a beneficial ownership of 2,487,468 shares of RxSight, Inc. (RXST) common stock, representing 6.0% of the class. This stake was reported as of August 18, 2026, through a Schedule 13G filing, indicating shared voting and dispositive power. The shares are managed by Point72 Asset Management via Point72 Associates, LLC, an investment fund.
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST
Vitruvian Partners LLP has acquired a new stake of 278,865 shares in RxSight, Inc. (NASDAQ:RXST) during the second quarter, making it their 8th largest holding and representing approximately 0.7% of their investment portfolio. Despite this new investment and RxSight beating quarterly earnings expectations, the company currently holds an average analyst rating of "Reduce" with a target price of $8.37. Other institutional investors have also adjusted their positions in RxSight, with institutional ownership reaching 78.78%.
RxSight (NASDAQ: RXST) ex-director to sell 11,890 shares
RxSight, Inc. (NASDAQ: RXST) has reported through a Form 144 SEC filing that former director Raymond W. Cohen intends to sell 11,890 shares of common stock. The proposed sale, valued at $75,748.81, will be executed via Morgan Stanley Smith Barney LLC on NASDAQ. This disclosure signals a potential insider sale under Rule 144, rather than a company-initiated transaction.
Walleye Capital LLC Takes Position in RxSight, Inc. $RXST
Walleye Capital LLC has acquired a new stake of 358,036 shares in RxSight, Inc. (NASDAQ:RXST) during the second quarter, valued at approximately $1.73 million. Despite institutional ownership of 78.78%, RxSight carries a consensus "Reduce" rating from analysts with an average price target of $8.37. The company recently reported better-than-expected quarterly revenue and a narrower loss per share, though it continues to operate with negative margins and is projected to lose $1.31 per share for the current year.
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages
RxSight, Inc. (NASDAQ:RXST) has received a consensus "Reduce" rating from twelve analysts, with an average 12-month price target of $8.37. Despite several firms lowering their price targets, the company's latest quarterly results surpassed expectations. Institutional investors hold a significant 78.78% stake in RxSight.
Stifel cuts RxSight stock price target on competitive headwinds
Stifel has lowered its price target for RxSight Inc. (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a Hold rating due to anticipated competitive headwinds over the next 12-18 months. Despite the company surpassing second-quarter 2026 earnings and revenue expectations, and the new CEO Aziz Mottiwala bringing relevant experience, RxSight withdrew its full-year guidance, which led to a stock decline. The firm anticipates a challenging environment for RxSight to expand beyond its niche given the evolving multifocal IOL market.
Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00
Stifel Nicolaus has reduced its price target for RxSight (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a "hold" rating, suggesting an 11.82% potential upside. Despite the lowered target, RxSight recently reported better-than-expected quarterly results, surpassing analyst estimates for both earnings per share and revenue. The company currently holds a "Reduce" consensus rating from analysts, with an average price target of $8.37.
Stifel cuts RxSight stock price target on competitive headwinds
Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) to $7.00 from $8.00 due to competitive headwinds, while maintaining a Hold rating. Despite the stock appearing undervalued and recent Q2 2026 earnings beating expectations, the company withdrew its full-year guidance. Stifel anticipates a turnaround will take time, given the evolving multifocal IOL landscape.
RxSight (RXST) offers to swap 4.08M underwater options for new awards
RxSight, Inc. has initiated an employee stock option exchange offer for up to 4,083,693 underwater options issued under its 2021 Equity Incentive Plan. Eligible U.S.-based employees can exchange options with exercise prices at or above $6.00 (or $10.00 for named executive officers) for new awards, which will be restricted stock units for non-executive employees and new stock options for named executive officers. The offer aims to replace outstanding, unexercised options with new awards, conditional on employee participation and company acceptance.
RxSight Reports Q2 Financial Results, Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for Q2 2026, reporting $33.7 million in total revenue, including $6.5 million from a collaboration with Alcon. Product sales decreased by 19 percent due to competitive pressures. The company also announced a leadership transition and withdrew its 2026 guidance, expecting to resume formal guidance in early 2027.
Wall Street Zen Upgrades RxSight (NASDAQ:RXST) to Hold
Wall Street Zen has upgraded RxSight (NASDAQ:RXST) from a "sell" to a "hold" rating, while the broader analyst consensus remains "Reduce" with an $8.59 average price target. This upgrade follows RxSight reporting better-than-expected quarterly results, with a loss of $0.29 per share against an estimated $0.33 loss and revenues of $33.74 million surpassing the $32.55 million estimate. Institutional investors currently hold 78.78% of the company's shares.
Levi & Korsinsky Notifies RxSight, Inc. (RXST) Investors - Lead Plaintiff Deadline on September 22, 2025
Levi & Korsinsky LLP has announced a lead plaintiff deadline of September 22, 2025, for investors of RxSight, Inc. (RXST) who suffered losses. The class action securities lawsuit alleges that RxSight made false statements regarding "adoption challenges," overstated product demand, and was unlikely to meet its financial guidance for fiscal year 2025. Investors are encouraged to seek recovery under federal securities laws.
RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside
RxSight, Inc.'s average stock price target has been reduced from $8.06 to $7.91 by 8 analysts, with individual forecasts ranging from $6 to $11 per share. This new target suggests a potential upside of approximately 26% based on the recent closing price. The consensus rating for RxSight, Inc. remains "Hold" among 10 analysts.
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside
RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite a current "Hold" recommendation from brokerage firms. The company's revenue and earnings estimates for both 2026 and 2027 have seen upward revisions in the last 90 days.
Rxsight, Inc. Reports Second Quarter 2026 Res
This article is a placeholder indicating that Rxsight, Inc. reported its second quarter 2026 results. The full content of the report is not provided.
Press Release: RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for the second quarter of 2026. The company also provided an update on its financial outlook for the full year 2026. This press release details their performance and future expectations.
RxSight Q2 Earnings Call Highlights
RxSight reported Q2 revenue of $33.7 million, with product sales down 19% year-over-year excluding collaboration revenue, due to competitive trialing and market headwinds. The new CEO, Aziz Mottiwala, has withdrawn full-year financial guidance to conduct a comprehensive assessment of the business and commercial strategy, with a focus on improving LAL platform adoption and utilization. The company expects to resume formal guidance in early 2027 after reporting Q4 2026 results.
New RxSight lenses are intended to reduce post-surgery office visits
RxSight, Inc. (NASDAQ: RXST) reported Q2 2026 revenue of $33.7 million, flat year-over-year, and a net loss of $12.1 million. The company announced a strategic collaboration with Alcon, appointed a new CEO, and introduced a next-generation Light Adjustable Technology platform with new lenses designed to improve workflow and reduce postoperative office visits. Due to a leadership transition, RxSight withdrew its 2026 guidance, with plans to resume formal guidance in early 2027.
RxSight Q2 FY26 net loss widens 2.6% to $12.1 million; revenue rises 0.3% to $33.7 million
RxSight reported a Q2 FY26 net loss of $12.1 million, a 2.6% increase, despite a 0.3% rise in revenue to $33.7 million. The revenue increase was primarily driven by a $6.5 million license fee, which offset a 19% decline in product sales. The company's product gross margin also fell, and Aziz Mottiwala was named CEO, effective July 20.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) reported a narrower-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, and surpassed revenue estimates with $33.74 million. Despite beating estimates, the company's shares have fallen 40% year-to-date, while the broader S&P 500 gained 13%. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance
RxSight reported better-than-expected Q2 2026 earnings and revenue, but its stock fell after the company withdrew its full-year guidance due to ongoing pressure in its core business. The ophthalmology company's adjusted EPS beat estimates by $0.25, and revenue topped forecasts, partly aided by a collaboration with Alcon. However, core product revenue declined 19% year-over-year, leading the company to re-evaluate its commercial model.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for the second quarter of 2026, reporting total revenue of $33.7 million, which included $6.5 million from its collaboration with Alcon. The company also announced the appointment of Aziz Mottiwala as President and CEO, and revealed plans to develop a next-generation RxSight Light Adjustable Technology platform. Due to the leadership transition and a comprehensive business review, RxSight withdrew its 2026 financial guidance, with plans to resume formal guidance in early 2027.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. reported its financial results for the second quarter of 2026, with total revenue reaching $33.7 million, including $6.5 million from its collaboration with Alcon. The company also announced key strategic developments, such as the appointment of Aziz Mottiwala as CEO and a strategic collaboration with Alcon, while withdrawing its 2026 financial guidance to focus on strengthening commercial execution and business review. Despite a net loss of $(12.1) million, RxSight aims to translate the value of its adjustable lens technology into durable growth, backed by approximately $209 million in cash and short-term investments.
RxSight, Inc. (RXST) Tops Q2 EPS by 25c
RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2, with earnings per share of ($0.11), significantly surpassing analyst estimates of ($0.36) by $0.25. The company's revenue also exceeded expectations, coming in at $33.74 million against a consensus estimate of $32.21 million.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) reported a smaller-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, though it was still a wider loss compared to the previous year. The company also surpassed revenue estimates, posting $33.74 million against an expectation of $32.90 million. Despite these Q2 beats, RxSight shares have fallen significantly this year, and the stock currently holds a Zacks Rank #3 (Hold).
RxSight (RXST): Millennium entities, Israel Englander report 7.3% ownership stake
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 7.3% ownership stake in RxSight, Inc. (RXST), totaling 3,030,287 shares as of June 30, 2026. The filing indicates that all beneficially owned shares have shared voting and dispositive power, with no sole voting or dispositive power reported by the individual entities. A Joint Filing Agreement among the reporting persons was executed on August 3, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. Investors who purchased RxSight securities before November 7, 2024, and continue to hold them, are encouraged to contact the firm to assist in the investigation.
RxSight, Inc. expected to post a loss of 33 cents a share - Earnings Preview
RxSight, Inc. is projected to report an earnings loss of 33 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which aggregates news from various sources including Reuters.
(RXST) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Rxsight Inc. (NASDAQ: RXST), highlighting strong near- and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 98.0:1 risk-reward setup, targeting a 34.3% gain against 0.4% risk. The report provides AI-generated institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis
Rxsight Inc (RXST) has a current financial score of 6.86, placing it 125 out of 199 in the Healthcare Equipment & Supplies industry. The company's financial status is stable with average operating efficiency, though its latest quarterly revenue decreased by 18.48% year-over-year and net profit saw a 93.94% year-over-year decrease. Key financial metrics like cash and cash equivalents, total assets, and cash flow from operating activities were not fully disclosed.
